Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
Riikonen
Raili
R
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D018450:Disease Progression; D006801:Humans; D007223:Infant; D010468:Perceptual Disorders / Q000139:chemically induced*; D013036:Spasms, Infantile / Q000188:drug therapy; D020888:Vigabatrin / Q000009:adverse effects* / Q000494:pharmacology* / Q000627:therapeutic use; D014794:Visual Fields / Q000187:drug effects*
D000927:Anticonvulsants; D020888:Vigabatrin